Patent US4920125A successfully refreshed from Google Patents.
US4920125A
Expired / Lapsed
US
⏱️ 0.0 years remaining
L-glutamic acid derivatives
Assignee: Princeton University
•
Filing: 1989-08-29
•
Granted: 1990-04-24
•
Expires: 2009-08-29
Abstract
Abstract Pyrimidin-5-yl derivatives of L-glutamic acid are anti-neoplastic agents. A typical embodiment is N-(4-[5-(2,6-diamino-4-hydroxypyrimidin-5-yl)-butyl]-thien-2-ylcarboxy)-L-glutamic acid.
Inventors
- 👤 Edward C. Taylor
- 👤 Philip M. Harrington
- 👤 Chuan Shih
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 14:38
CPC Classifications
C; C07; C07D; C07D409/00; C07D409/02; C07D409/06; A; A61; A61P; A61P35/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
33 words
A compound of the formula: ##STR9## in which n has a value of 2 to 6; and the configuration about the carbon atom designated * is L; and the pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
33 words
A compound of the formula: ##STR9## in which n has a value of 2 to 6; and the configuration about the carbon atom designated * is L; and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
16 words
A compound according to claim 1 in which n has a value of 3 to 5.
Claim 4
Dependent Claim
11 words
A compound according to claim 2 in which n is 4.
Claim 5
Dependent Claim
10 words
The compound according to claim 1 which is N-(4-[4-(2,6-diamino-4-hydroxypyrimidin-5-yl)butyl]thien-2-ylcarboxy)-L-glutamic acid.
Claim 6
Dependent Claim
10 words
The compound according to claim 1 which is N-(5-[4-(2,6-diamino-4-hydroxypyrimidin-5-yl)butyl]thien-2-ylcarboxy)glutamic acid.
Claim 7
Dependent Claim
32 words
The method of combating neoplastic growth in a mammal which comprises administering to the mammal in a single or multiple dose regimen an effective amount of a compound according to claim 1.
Claim 8
Dependent Claim
47 words
A pharmaceutical composition for combating neoplastic growth in a mammal which comprises an amount of a compound according to claim 1 which upon administration to the mammal in a single or multiple dose regimen is effective to combat said growth, in combination with a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US4339453A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-23 | 1993-10-23 | 1994-04-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-23 | 1997-10-23 | 1998-04-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-23 | 2001-10-23 | 2002-04-24 | $7700.00 | Window Closed / Lapsed |